John Montana, an experienced drug developer, has joined Forbion Capital Partners as an operating partner to help the Netherlands-based venture capital firm manage new investment opportunities. Dr Montana joins from Charles River Laboratories where he oversaw integrated drug discovery projects. He has also been chief scientific officer of Paradigm Therapeutics prior to the company’s acquisition by Takeda Pharmaceutical Co Ltd. Dr Montana earned a PhD in medicinal chemistry from the University of East Anglia, UK.
Forbion announced the appointment on 29 January 2020.
Copyright 2020 Evernow Publishing Ltd